Alvocidib

Generic Name: Alvocidib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₀ClNO_₅

CAS Number: 146426-40-6

Unique Ingredient Identifier: 45AD6X575G

Background: Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

Indication: Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: alvocidib

First Posted Date: 2004-09-06

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00003039

Locations: 🇺🇸
Clinical Sciences Building, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Cancer Care Specialists of Central Illinois, S.C., Decatur, Illinois, United States

and more 7 locations

Flavopiridol in Treating Patients With Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: alvocidib

First Posted Date: 2004-08-02

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00003256

Locations: 🇺🇸
Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Phase 1

Completed

Conditions: Refractory Plasma Cell Myeloma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Drug: Bortezomib
Drug: Alvocidib Hydrochloride
Other: Pharmacological Study

First Posted Date: 2004-05-19

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 93

Registration Number: NCT00082784

Locations: 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

and more 2 locations

Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Epithelial Cancer
Stage IIIA Ovarian Epithelial Cancer
Stage IIIB Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IIIA Primary Peritoneal Cavity Cancer
Stage IIIC Ovarian Epithelial Cancer
Stage IIIB Primary Peritoneal Cavity Cancer
Stage IIIC Primary Peritoneal Cavity Cancer
Stage IV Primary Peritoneal Cavity Cancer

Interventions: Drug: cisplatin
Drug: alvocidib
Drug: cisplatin/flavopiridol

First Posted Date: 2004-05-17

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00083122

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Flavopiridol in Treating Patients With Refractory Cancer

Phase 1

Completed

Conditions: Lymphoma
Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Small Intestine Cancer

First Posted Date: 2004-04-21

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019344

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: fluorouracil
Drug: oxaliplatin
Drug: leucovorin calcium

First Posted Date: 2004-04-08

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00080990

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: gemcitabine hydrochloride
Drug: irinotecan hydrochloride

First Posted Date: 2004-03-10

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00079352

Locations: 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: gemcitabine hydrochloride
Drug: alvocidib
Other: pharmacological study

First Posted Date: 2003-11-06

Last Posted Date: 2013-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00072436

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: gemcitabine hydrochloride

First Posted Date: 2003-10-15

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00007917

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

Phase 1

Terminated

Conditions: Hematopoietic/Lymphoid Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Other: pharmacological study
Radiation: fludeoxyglucose F 18
Other: fluorine F 18 fluorothymidine
Procedure: positron emission tomography

First Posted Date: 2003-10-07

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00070239

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy